<DOC>
	<DOCNO>NCT01759654</DOCNO>
	<brief_summary>This open study use AdimFlu-V ( 2012-2013 season ) vaccine non-elderly elderly subject . All participates receive one dose vaccine ( 0.5 ml ) intramuscular injection upper arm . Safety outcomes include immediate reaction time vaccination , solicit local systemic reaction 7 day , unsolicited adverse event 28 day , serious adverse event . Sera prepare blood sample collect subject immediately prior , 28 day vaccination . Anti-hemagglutinin ( HA ) antibody titer determine use WHO hemagglutination inhibition reference technique . The central laboratory responsible antibody titration aware background blood sample ( e.g. , pre- post-serum ) , also call observer-blinded . All participates follow , either clinical visit telephone contact , 8 week vaccination safety reason .</brief_summary>
	<brief_title>A Trial Assess Immunogenicity Safety Trivalent Virosomal Influenza Vaccine , Formulation 2012-2013 , Non-Elderly Adults Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Males nonpregnant female age less 18 year ; 2 . Willing able adhere visit schedule study requirement ; 3 . Subjects willing provide sign studyspecific inform consent . 1 . Subject his/her family employ participated hospital ; 2 . Subjects receive influenza vaccine within previous 6 month ; 3 . History hypersensitivity egg hen 's protein , polymyxin B , neomycin , similar pharmacological effect study vaccine ; 4 . Personal family history GuillainBarré Syndrome ; 5 . An acute febrile illness within 1 week prior vaccination ; 6 . Current upper respiratory illness , include common cold nasal congestion within 72 hour ; 7 . Subjects influenzalike illness define presence fever ( temperature le 38°C ) least two follow four symptom : headache , muscle/joint ache pain ( e.g . myalgia/arthralgia ) , sore throat cough ; 8 . Female subject pregnant , lactate likely become pregnant study ; woman childbearing potential disagree use acceptable method contraception ( e.g. , hormonal contraceptive , intrauterine device ( IUD ) , barrier device abstinence ) throughout study ; 9 . Treatment investigational drug device , participation clinical study , within 3 month study vaccination ; 10 . Immunodeficiency , immunosuppressive treatment ; 11 . Receipt live virus vaccine within 1 month prior study vaccination expect receipt within 1 month study vaccination ; receipt inactivate vaccine within 2 week prior study vaccination expect receipt within 1 month study vaccination ; 12 . Receipt blood product , include immunoglobulin prior 3 month ; 13 . Underlying condition investigator ' opinion may interfere evaluation vaccine ; 14 . Significant chronic illness inactivate influenza vaccine recommend commonly use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>